钙调神经磷酸酶抑制剂不耐受患者换用贝拉西普后抗病毒免疫效力保留且无同种免疫
研究比较肾移植术后3个月内从钙调神经磷酸酶抑制剂(CNI)换用贝拉西普的患者与匹配的CNI方案对照患者,通过免疫表型与细胞内细胞因子染色评估同种免疫和抗病毒免疫。换用贝拉西普后供者特异性免疫应答无显著变化,对照组出现供者特异性抗体(DSA)而贝拉西普组无,病毒特异性(CMV、EBV)免疫应答两组相似且随时间稳定。
要点
- 换用贝拉西普后naive T细胞减少、TMRA T细胞增加,与对照组无显著差异。
- 对照组出现DSA而贝拉西普组无(naive P=0.039,TMRA P=0.002)。
- 对照组新发DSA发生率更高(P=0.035),病毒特异性免疫应答两组相似且稳定。
核心结论
- 对于从CNI方案换用贝拉西普的患者,贝拉西普使用与无同种反应性相关,且不影响免疫表型,同时保留抗病毒免疫应答。
研究设计与样本
- 研究纳入肾移植术后3个月内从CNI换用贝拉西普的患者,与匹配的CNI方案对照患者进行比较。
- 通过免疫表型分析和细胞内细胞因子染色(ICS)评估同种免疫和抗病毒免疫。
- 临床试验注册号:NCT01953120。
主要发现
- 换用贝拉西普后免疫表型显示naive T细胞减少、终末分化效应记忆(TMRA)T细胞增加,与对照患者无显著差异。
- 通过ICS测量的供者特异性免疫应答在单细胞因子或双细胞因子分泌方面均无显著变化,但对照组出现供者特异性抗体(DSA)而贝拉西普组无(naive P=0.039,TMRA P=0.002)。
- 对照组新发DSA发生率更高(P=0.035)。
- 针对巨细胞病毒(CMV)或EB病毒(EBV)的病毒特异性免疫应答两组相似且随时间稳定。
关键数值与推荐
- 对照组出现DSA而贝拉西普组无:naive亚型P=0.039,TMRA亚型P=0.002。
- 对照组新发DSA发生率更高:P=0.035。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Belatacept has shown potential for prevention of rejection after kidney transplantation, given its demonstration of reduced nephrotoxicity in combination with absence of significant incidence of rejection. However, concerns have been raised regarding increased risk of viral infection. METHODS: We set out to explore the impact of the switch to belatacept on alloimmune and antiviral immunity through the study of patients switched from calcineurin inhibitor (CNI) to belatacept within 3 months of kidney transplantation compared with a matched cohort of control patients on a CNI-based regimen. RESULTS: After the switch to belatacept, immune phenotyping demonstrated a decrease in naive and an increase in terminally differentiated effector memory (TMRA) T cells, with no significant difference compared with control patients. Donor-specific immune response, measured by intracellular cytokine staining (ICS), did not change significantly either by single or double cytokine secretion, but it was associated with the appearance of donor-specific antibody (DSA) in the control but not the belatacept cohort (P = 0.039 for naive and P = 0.002 for TMRA subtypes). Increased incidence of de novo DSA development was observed in the control group (P = 0.035). Virus-specific immune response, as measured by ICS in response to cytomegalovirus (CMV) or Epstein-Barr virus (EBV), was similar in both groups and stable over time. CONCLUSION: We found that belatacept use was associated with an absence of alloreactivity without impact on immune phenotype, while preserving the antiviral immune response, for patients switched from a CNI-based regimen. In parallel, the antiviral immune response against CMV and EBV was preserved after the belatacept switch (clinicaltrials.gov: NCT01953120).
引用
- Schaenman J, Rossetti M, Pickering H, et al. Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor-Intolerant Patients. Kidney Int Rep. 2022. PMID: 36644348. doi:10.1016/j.ekir.2022.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。